Clinical Trial for MEDI-551 in Scleroderma Completed

Author: Maureen Newman
Date Published: January-2015
Source: Scleroderma News

A Phase 1 clinical trial recently ended that involved “A Study of the Safety and Tolerability of MEDI-551 in Scleroderma.” MedImmune LLC, sponsor of the study, last updated the results of the trial in an abstract presented through Annals of the Rheumatic Diseases. According to “Safety and Tolerability of MEDI-551 in Subjects with Systemic Sclerosis (SSC): Results from A Phase 1 Randomized, Placebo-Controlled Escalating Single-Dose Study,” the pharmacodynamics and safety profile of MEDI-551 warrant further clinical development. Although patients taking MEDI-551 experienced adverse and serious events potentially due to treatment, and patients taking placebo experienced none, events were singular, and the only death was related to scleroderma worsening, not treatment.